Biological effects of a dietary omega-3 polyunsaturated fatty acids supplementation in cystic fibrosis patients: a randomized, crossover placebo-controlled trial

Clin Nutr. 2006 Jun;25(3):418-27. doi: 10.1016/j.clnu.2005.10.011. Epub 2005 Dec 2.

Abstract

Background and aims: Various anti-inflammatory therapies, including dietary omega-3 polyunsaturated fatty acids (PUFA) supplementation, have been investigated in cystic fibrosis (CF) patients. To further explore this nutritional approach, biological effects of an omega-3 PUFA oral liquid supplementation were measured in 17 CF patients in a double-blind, randomized, crossover without a washout period and placebo-controlled study.

Methods: CF patients (age: 18+/-9 year; weight: 43+/-13 kg) received a liquid dietary supplementation either enriched or not in omega-3 PUFA (390-1170 mg/day according to patient weight) during two 6-month periods.

Results: Increase in eicosapentaenoic acid was observed in neutrophil membrane following omega-3 PUFA dietary supplementation (from 0.7+/-0.6 to 1.6+/-0.6 micromol%, P<0.01). The leukotriene B(4) (LTB(4))/leukotriene B(5) (LTB(5)) ratio was decreased (from 72+/-27 to 24+/-7, P<0.001) in CF patients taking omega-3 PUFA supplements. In contrast, omega-3 PUFA supplementation affected neither internalization of IL-8 receptors following IL-8 exposure, nor IL-8-induced neutrophil chemotaxis.

Conclusion: Our results show that omega-3 PUFA are incorporated in neutrophil membranes. The subsequent decrease in LTB(4)/LTB(5) ratio suggests that, in such conditions, neutrophils may produce less pro-inflammatory mediators from the acid arachidonic pathway. These data indicate that omega-3 PUFA intake may have anti-inflammatory effect that still need to be assessed by long-term studies following large groups of patients.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Cell Membrane / chemistry
  • Chemotaxis, Leukocyte / drug effects
  • Child
  • Cross-Over Studies
  • Cystic Fibrosis / therapy*
  • Dietary Supplements
  • Eicosapentaenoic Acid / analogs & derivatives
  • Eicosapentaenoic Acid / blood
  • Fatty Acids, Omega-3 / administration & dosage*
  • Humans
  • Interleukin-8 / pharmacology
  • Leukotriene B4 / analogs & derivatives
  • Leukotriene B4 / blood
  • Neutrophils / ultrastructure
  • Placebos
  • Receptors, Interleukin / drug effects
  • Receptors, Interleukin / metabolism

Substances

  • Fatty Acids, Omega-3
  • Interleukin-8
  • Placebos
  • Receptors, Interleukin
  • Leukotriene B4
  • leukotriene B5
  • Eicosapentaenoic Acid